Single‐cell RNA sequencing reveals SERPINE1‐expressing CAFs remodelling tumour microenvironment in recurrent osteosarcoma

骨肉瘤 癌相关成纤维细胞 肿瘤微环境 癌症研究 运行x2 细胞 Wnt信号通路 癌症 细胞生长 生物 计算生物学 基因表达 基因 遗传学 肿瘤细胞
作者
Xin Huang,Lutong Wang,Haoyu Guo,Weiyue Zhang
出处
期刊:Clinical and translational medicine [Springer Science+Business Media]
卷期号:14 (1) 被引量:7
标识
DOI:10.1002/ctm2.1527
摘要

Dear Editor, Osteosarcoma (OS) is widely regarded as the most common bone tumour, mainly affecting young adults.1 Cancer-associated fibroblasts (CAFs), which are highly infiltrated in the tumour microenvironment (TME), could act as a novel target for cancer immunotherapy.2, 3 Single-cell RNA sequencing (scRNA-seq) has been regarded as one potent new method to investigate TME. We aim to uncover the roles of CAFs in recurrent OS with scRNA-seq and further provided novel treatment strategies for OS. Our study conducted scRNA-seq and bioinformatic analysis to uncover cellular clusters of OS tumour tissues. The cellular clusters of OS lesions were explored via two Gene Expression Omnibus (GEO) datasets of GSE152048 (BC) and GSE162454 (OS). Moreover, three paired OS lesions were utilised to further confirm the outcomes. After quality control, these two datasets were grouped into 14 cell clusters with the Uniform Manifold Approximation and Projection (UMAP) method according to the corresponding biomarkers (Figure 1A). Div-cells are the MKI67+ diverse cells with improved proliferation. We identified the cells in TME including: OS cells (COL1A1+, RUNX2+, ALPL+), Div-OS cells (COL1A1+, RUNX2+, ALPL+; TOP2A+, MKI67+), CAFs (ACTA2+/α-smooth muscle actin (α-SMA), COL1A1+, FGF7+), Div-CAFs (ACTA2+/α-SMA, COL1A1+, TOP2A+, FGF7+, MKI67+), macrophages (CD74+, CD14+, C1QA+, C1QB+) and so on. The UMAP plots of cell clusters (Figure 1B) and the relative proportion of every cluster (Figure 1C) in these two datasets were shown. Recurrent samples (BC11 and BC20) had a higher infiltrate of Div-CAFs than other samples (Figure S1A). As for the 'metastasis' and 'recurrent' samples, 'metastasis' refers to the samples collected from the lung metastatic OS lesions, and 'recurrent' refers to the samples collected from recurrent OS lesions. Based on the above cell clusters in different OS tissues shown via the UMAP plots (Figure 1D), we found that CAFs were more highly infiltrated in recurrent OS than the primary OS (96.42% vs. 3.58%). The Differentially expressed genes (DEGs) among different OS tissues were further studied. Based on the pathway enrichment analysis, we found the significantly activated the epithelial-to-mesenchymal transition (EMT) pathway in recurrent OS (Figure 1E, shown by green arrow), which showed the heterogeneity of gene expressions among different OS tissues. Furthermore, the density heatmap and scatterplot of Gene Set Enrichment Analysis (GSEA) indicated that CAFs were remarkably associated with EMT hallmark gene sets (Figure 1F,G). As shown by Figure 1G, EMT sets have the maximum density in the cell cluster of CAFs. To sum up, CAFs were highly infiltrated and associated with the EMT in recurrent OS. The DEGs in different OS tissues were shown (Figure 1H). Moreover, SERPINE1 was significantly higher in Div-CAFs of recurrent OS (Figure 1I). SERPINE1 is also termed plasminogen activator inhibitor 1 (PAI1), and its encoded protein inhibits the fibrinolysis process. A previous study has shown that SERPINE1 functions as a target gene of microRNA to promote the invasion and metastasis of OS.4 SERPINE1 has been reported as a pro-tumourigenesis factor and a member of the EMT way, which suggested that SERPINE1 enables tumour cell growth and invasion.5 Furthermore, we tried to identify the clinical characterisations of SERPINE1-expressing CAFs. Cumulative survival curves indicated that SERPINE1 was associated with a poor prognosis of sarcoma (Figure 1J). Moreover, SERPINE1 was significantly associated with the EMT markers (Figure 1K). Accordingly, SERPINE1 might contribute to the EMT of OS, thereby serving as a novel biomarker for recurrent OS. To validate the findings above, we explored the functions of CAFs in recurrent OS. By TIMER database, fibroblast activation protein (FAP) of CAFs was significantly associated with EMT markers (Figure S1B). By western blot, increased N-cadherin or decreased E-cadherin expression was shown in CAFs rather than OS cells (Figure S1C,D). As shown by immunofluorescence (IF) staining, the increased α-SMA and decreased E-cadherin expressions were shown in recurrent OS (Figure S1E). To sum up, it was indicated that CAFs were remarkably associated with EMT markers in recurrent OS. The functions of SERPINE1 in vivo were further studied. Nude mice (BALB/c-nu, female, 4−5 weeks) were injected subcutaneously with 5 × 106 MNNG/HOS cells. The tumour tissues were further treated by the injection of si-SERPINE1 or si-NC. Compared with si-NC group, si-SERPINE1 remarkably inhibited the tumour volume (Figure 2A). SERPINE1 was remarkably downregulated in si-SERPINE1 group via Immunohistochemistry (IHC) (Figure 2B,E). The Ki67+ cells significantly decreased (Figure 2C,E) but TUNEL positive cells increased (Figure 2D,E) because of si-SERPINE1. The above results suggested that SERPINE1 knockdown has significantly anti-OS effects. IF staining indicated that the relative proportion of CAFs was significantly lower in si-SERPINE1 group (Figure 2F). We found that IL1B of Div-Macrophages was significantly downregulated (Figure 2G). SERPINE1 has a positive correlation with CD163 (r = .443, p = 0e-00), which is the marker of M2 macrophages (Figure 2H). Moreover, in si-SERPINE1, M1 macrophages (iNOS) remarkably increased (Figure 2I). Therefore, SERPINE1 could regulate macrophage polarisation and inhibit OS progression in vivo. As shown in Figure 3A, this study used the co-culture systems to investigate the underlying mechanisms of SERPINE1 in the TME. CAFs transfected with si-SERPINE1 had lower expression levels of the stromal activation markers including α-SMA and FAP (Figure 3B,C). Accordingly, SERPINE1 is important in promoting the activity of CAFs. As for the lower chamber, OS cells in si-SERPINE1 group showed decreased N-cadherin and increased E-cadherin expressions (Figure 3D). Furthermore, the relative proportion of M2 macrophages (CD163) in si-SERPINE1 group remarkably reduced (Figure 3E,F). To sum up, SERPINE1 could regulate the activity of CAFs, further induce macrophage polarisation to facilitate OS recurrence. The heterogeneity in TME among different tumours remains to be explored.6 The scRNA-seq technology is widely used to identify the cellular groups in TME.7, 8 Compared with primary OS, we found that recurrent OS was featured by higher CAFs levels in TME via scRNA seq analysis. Moreover, the increased infiltrating CAFs were associated with the EMT in recurrent OS. Thus, this validated that CAFs could mediate OS recurrence. As for the detailed mechanisms, SERPINE1 had the highest expression in CAFs of recurrent OS. SERPINE1 has been widely known to regulate the progression of numerous cancers, which highlights the application of SERPINE1 as a potential target.9, 10 We validated that SERPINE1 was remarkably correlated with macrophage infiltrations and the EMT of OS. Knocking down SERPINE1 by si-SERPINE1 could decrease CAFs infiltration and activity, and inhibit OS progression via inducing M1 macrophage polarisation (Figure 4). To sum up, we uncovered the characteristics of recurrent OS and the roles of SERPINE1-expressing CAFs in regulating TME. SERPINE1 could regulate the activity of CAFs, further induce macrophage polarisation and regulate EMT pathway to facilitate OS recurrence. Accordingly, targeting SERPINE1-expressing CAFs had shown promising efficacy in treating recurrent OS. In the future, with the development of single-cell multi-omics technologies, we might precisely regulate the SERPINE1-expressing CAFs in the TME, thereby contributing to the precise targeted therapy in OS. Investigation, supervision and writing—original draft: Xin Huang. Investigation and methodology: Haoyu Guo and Lutong Wang. Conceptualisation, funding and writing—review and editing: Xin Huang and Weiyue Zhang. This study is supported by the National Natural Science Foundation of China (82203059 and 82300932) and the Hubei Natural Science Foundation (2022CFB656). The authors declare they have no conflicts of interest. This study was approved by the Institutional Animal Care and Use Committee of Huazhong University of Science and Technology (IACUC number 3068). Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
上邪发布了新的文献求助10
2秒前
丘比特应助Zzz采纳,获得10
3秒前
整齐荟完成签到,获得积分10
3秒前
....发布了新的文献求助10
3秒前
3秒前
帅气忆南发布了新的文献求助10
3秒前
Mm15s完成签到,获得积分10
4秒前
4秒前
爱弥儿发布了新的文献求助10
4秒前
gorgeousgaga完成签到,获得积分10
5秒前
王w发布了新的文献求助30
6秒前
6秒前
Crazy_Runner发布了新的文献求助10
7秒前
小琳发布了新的文献求助10
7秒前
7秒前
8秒前
金金金完成签到,获得积分10
8秒前
NexusExplorer应助典雅雪珍采纳,获得10
8秒前
9秒前
10秒前
liuzhanyu发布了新的文献求助10
10秒前
10秒前
小白完成签到,获得积分10
10秒前
11秒前
13秒前
xixi完成签到 ,获得积分10
13秒前
LittleWang发布了新的文献求助10
14秒前
万能图书馆应助顺利天蓉采纳,获得10
14秒前
朴素浩然发布了新的文献求助10
14秒前
我想想发布了新的文献求助10
15秒前
wangxinyao发布了新的文献求助10
15秒前
16秒前
16秒前
严兴明完成签到,获得积分10
17秒前
liuzhanyu发布了新的文献求助30
17秒前
慕青应助LL采纳,获得10
17秒前
18秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
PowerCascade: A Synthetic Dataset for Cascading Failure Analysis in Power Systems 2000
The Composition and Relative Chronology of Dynasties 16 and 17 in Egypt 1500
Picture this! Including first nations fiction picture books in school library collections 1500
Signals, Systems, and Signal Processing 610
Unlocking Chemical Thinking: Reimagining Chemistry Teaching and Learning 555
Rheumatoid arthritis drugs market analysis North America, Europe, Asia, Rest of world (ROW)-US, UK, Germany, France, China-size and Forecast 2024-2028 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6366215
求助须知:如何正确求助?哪些是违规求助? 8180121
关于积分的说明 17244782
捐赠科研通 5420994
什么是DOI,文献DOI怎么找? 2868279
邀请新用户注册赠送积分活动 1845424
关于科研通互助平台的介绍 1692912